BNDD –TEST PAGE

Includes a Live In-Person Event on 06/14/2027 at 8:00 AM (EDT)

  • You must log in to register
    • Early bird pricing available!
    • Nonmember - $1,950
    • Full Member - $1,650
    • Associate Member - $1,650
    • Emeritus Member - $1,650
    • Government Associate Member - $1,650
    • Government Full Member - $1,650
    • Postdoctoral Researcher/Transitional Member - $895
    • Student Member - $895
    • Regular Price after 04/22/2027 11:59 PM
    • Nonmember - $2,050
    • Full Member - $1,750
    • Associate Member - $1,750
    • Emeritus Member - $1,750
    • Government Associate Member - $1,750
    • Government Full Member - $1,750
    • Postdoctoral Researcher/Transitional Member - $995
    • Student Member - $995

This ACT course offers an in-depth exploration of regulatory considerations and the toxicologic evaluation and development of protein biologics, modified protein biologics, and specialized biologics, including cell and gene therapies, and oncolytic viruses. Participants gain a thorough understanding of the key principles and methodologies employed in the nonclinical safety assessment of these advanced therapeutic modalities. The curriculum covers a wide range of studies essential for advancing biotherapeutic drug candidates through all stages of drug development from candidate selection to marketing authorization. Topics include general toxicity studies and a variety of specialized studies, such as off-target assessment, safety pharmacology, carcinogenicity, and reproductive and developmental toxicity studies. Additionally, the course provides insight into pharmacokinetic and biodistribution assessments and the potential impact of immunogenicity for various of different therapeutic modalities. Several case studies are used to highlight how specific strategies and issues are approached in different scenarios.

The ACT course is offered exclusively in person. Virtual or hybrid participation options are not available.

Monday, June 14, 2027

Introduction to the Regulation of Biologics, Mary Ellen Cosenza, MEC Regulatory & Toxicology Consulting, LLC 

Traditional Biologics, Jeanine Bussiere, Amgen Inc. 

Carcinogenicity Assessment Strategies for Biotherapeutics, John Vahle, Lilly Research Laboratories

Case Studies and Q&A

Tuesday, June 15, 2027

Developmental and Reproductive Toxicity – Assessments and Considerations for Biopharmaceuticals, Wendy Halpern, Retired

Juvenile Toxicity, Wendy Halpern, Retired

Modified Molecules and Immunomodulators, Michael Leach, Trident Toxicology, Inc.

Nontraditional Strategies for Biopharmaceuticals, Michael Leach, Trident Toxicology, Inc.

Case Studies and Group Discussion, Mary Ellen Cosenza, MEC Regulatory & Toxicology Consulting, LLC, and Jeanine Bussiere, Amgen Inc.

Wednesday, June 16, 2027

Toxicology Study Data Interpretation, Mark Milton, Lake Boon Pharmaceutical Consulting, LLC 

Nonclinical to Clinical Translation, Jay Tibbitts, Gilead Sciences, Inc.  

Specialized Biologics: Cell Therapies, Hervé Lebrec, HL Toxicology and Preclinical Services

Preclinical Translation of Gene Therapy, Jessica Lynch, Johnson & Johnson

Speakers, presentation topics, and/or format are subject to change.

Detailed course handouts will be provided electronically. Participants must bring a personal computer to view materials. Please ensure to download materials before arriving. Internet will not be provided.

Times:

Registration and Check-In: Monday, 7:30 AM–8:00 AM

Course Presentations: Monday–Wednesday, 8:00 AM–5:00 PM

Jeanine L. Bussiere, PhD, DABT, ATS

Jeanine L. Bussiere, PhD, DABT, ATS

Scientific Executive Director

Amgen Inc.

Dr. Jeanine Bussiere is currently the Scientific Executive Director in Translational Safety and Bioanalytical Sciences (TS&BA) at Amgen having moved after the acquisition of Immunex in 2002, where she was the Director of Pharmacology/Toxicology for 3 years. Prior to joining Immunex, Dr. Bussiere was a scientist at Genentech for 8 years. Throughout her career, her work has focused on nonclinical safety supporting the development of biopharmaceuticals across a variety of therapeutic areas. Her additional expertise is in the area of immunotoxicology, and she received the Career Achievement Award from the Biotechnology Specialty Section in 2016. She is a Diplomate of the American Board of Toxicology, a Fellow of the Academy of Toxicological Sciences, and is an active member of the Society of Toxicology, serving on several committees, both elected and appointed. She is a member of the ILSI/HESI Immunotoxicology Technical Committee, and the American College of Toxicology and serves on the editorial board for the Journal of Immunotoxicology. She received her Doctorate from Washington State University and did her postdoctoral work at Temple University, with an emphasis in immunotoxicology. 

Mary Ellen Cosenza, PhD, MS, DABT, ATS, ERT, RAC

Mary Ellen Cosenza, PhD, MS, DABT, ATS, ERT, RAC

Consultant

MEC Regulatory and Toxicology Consulting

Dr. Mary Ellen Cosenza is a regulatory consultant with over 30 years of senior leadership experience in the biopharmaceutical industry in the US, Europe, and emerging markets. During her 20-year tenure at Amgen, she led the US Regulatory Department, the International Emerging Markets Regulatory Department, and served as an Executive Director of Global Regulatory Affairs and Safety, focusing on Early Development, Medical Writing, and Inflammation. In addition to her leadership roles in Regulatory Affairs, she also served as the Senior Director of Toxicology at Amgen. Prior to joining Amgen, she served as a Principal Scientist in Toxicology for the Medical Research Division of American Cyanamid Company (now Pfizer).  

While at Amgen, Dr. Cosenza was responsible for both early- and late-stage development programs resulting in numerous successful IND, CTA, NDA, MAA, and BLA submissions in a wide variety of therapeutic areas and modalities. In addition, she played a key leadership role in preparing teams for global health authority meetings with FDA, EMA, and regional country health authorities, including several FDA Advisory Committee Meetings.

Dr. Cosenza is recognized as an expert in preclinical biologic drug development and is a founding member of BIO’s BioSafe Preclinical Expert group. She was also a member of an Expert Working Group, operating under the auspices of the International Conference on Harmonization (ICH) for ICH M3(R2). Dr. Cosenza is well-published in the field of biological drug development, has authored several chapters on this topic, and recently co-edited a book on Translation Sciences focused on biologics and innovative products such as cell and gene therapies. She was also a co-editor of a Toxicological Pathology book for non-pathologists.

Dr. Cosenza is a Diplomat of the American Board of Toxicology, a Fellow of the Academy of Toxicological Sciences (current President), a member of the Society of Toxicology (SOT), Drug Information Association (DIA), and the Regulatory Affairs Professional Society (RAPS), and holds Regulatory Affairs Certification for both the US and EU. Dr. Cosenza is a European Registered Toxicologist (ERT) via the Royal Society of Biology, UK. She is also Treasurer of the International Union of Toxicology (IUTOX). Dr. Cosenza is a member of the American College of Toxicology (ACT), where she has served as a member of the ACT Education Committee, as Councilor, and as Treasurer and then President. She is an adjunct at the University of Southern California, where she teaches a graduate-level course on Food and Drug Toxicology and undergraduate classes on drug development and toxicology.

Dr. Cosenza received her PhD from St. John’s University, New York, and her MS in Regulatory Science from the University of Southern California, Los Angeles.

Wendy Halpern, DVM, PhD, DACVP

Wendy Halpern, DVM, PhD, DACVP

Retired

Dr. Wendy Halpern is a Veterinary Pathologist with more than 25 years of experience in the Biopharmaceutical Industry. She earned her DVM and MSc in Veterinary Pathology from the Ohio State University, and then completed a PhD in Biomedical Sciences at the University of New Mexico. She began her career at Human Genome Sciences, where she focused on several monoclonal antibody and fusion protein programs. In 2007, she moved to Genentech, where she spent the next 19 years in positions of increasing responsibility. She retired from Genentech in 2026 as a Senior Fellow in Translational Safety. Over her career, she has supported individual biopharmaceutical programs at all stages from pre-IND through post-market, and across both oncology and non-oncology indications, as well as collaborating across functions and mentoring within Translational Safety. Over the past 15 years, she has focused on nonclinical approaches to better understand and interpret reproductive and developmental toxicity, including dedicated support of pediatrics. She was a BioSafe contributing member for >20 years and served as the BIO representative on the ICH S11 working group from 2015-2020. She was also an active member of the HESI DART Technical Committee for the past 15 years and currently serves as a Councilor on the Executive Committee of the Society of Toxicologic Pathology. Additional professional affiliations include the American College of Veterinary Pathologists, Birth Defects Research and Prevention, and the Safety Pharmacology Society.

Jessica L. Lynch, PhD, DABT

Jessica L. Lynch, PhD, DABT

Distinguished Scientist II

Johnson & Johnson Innovative Medicine

Dr. Jessica L. Lynch is a Distinguished Scientist II in Preclinical Sciences & Translational Safety (PSTS) at Johnson & Johnson Innovative Medicine, where she serves as the Specialty Ophthalmology Disease Area Lead and Gene Therapy Modality Lead. She earned her PhD in Neuroscience from the University of Minnesota, is a Diplomate of the American Board of Toxicology, and has more than 15 years of experience advancing innovative therapies from discovery through regulatory submission and approval. In her current role, she provides strategic leadership for ophthalmology and gene therapy programs, guiding nonclinical safety strategies across multiple modalities while partnering closely with therapeutic area leaders, development teams, and regulatory agencies worldwide.  Dr. Lynch serves on multiple external committees in the gene therapy space, including the ASGCT translational science committee, BioSafe CGT working group, and EFPIA gene therapy working group.

Michael W. Leach, DVM, PhD, DACVP

Michael W. Leach, DVM, PhD, DACVP

President

Trident Toxicology, Inc.

Dr. Michael W. Leach is the President and Owner of Trident Toxicology, Inc. He is a veterinary pathologist, toxicologist, and drug developer with 3 decades of experience in the biopharmaceutical industry. Dr. Leach received his DVM from Purdue University, his PhD from the University of California, Davis, and is a diplomate of the American College of Veterinary Pathologists. He has worked for Schering-Plough, BASF Bioresearch Corporation, Abbott Bioresearch Center, Wyeth, and Pfizer with involvement in non-GLP early efficacy studies, in GLP-compliant toxicity studies and regulatory interactions supporting all phases of clinical development, in post-marketing activities, and in due diligence and licensing activities. He is an author/co-author on over 80 peer-reviewed papers, invited reviews, and book chapters.

His responsibilities and roles in various nonclinical drug safety organizations have included acting as a Study Pathologist, as Study Director, as a Therapeutic Area Head/Lead, as the Licensing and Acquisitions Lead, as the Biotherapeutics Safety Lead, and as the departmental representative to the Large Molecule Candidate Quality Guideline Committee; he also founded and led the Biotherapeutics Safety Leadership Team at Pfizer. Dr. Leach has previously served on the BioSafe Preclinical Safety Leadership Committee, the nonclinical safety committee within Biotechnology Innovation Organization (BIO). In 2023, Dr. Leach received the Career Achievement in Biotechnology Award from the Society of Toxicology Biotechnology Specialty Section. Dr. Leach has given over 40 invited presentations. He is a member of the American Veterinary Medical Association, the Society of Toxicology, the American College of Toxicology, the Society of Toxicologic Pathology, and the American College of Veterinary Pathologists. In his spare time, Dr. Leach enjoys scuba diving and underwater photography.

Hervé Lebrec, PharmD, PhD, DABT

Hervé Lebrec, PharmD, PhD, DABT

Consultant

HL Toxicology and Preclinical Services

Dr. Hervé Lebrec is the owner of HL Toxicology and Preclinical Services, a company providing consulting services in nonclinical safety assessment/toxicology. He has a proven record of driving strong, science-based strategies for the successful progression of therapeutic candidates at all stages of development. He built strong and diverse teams to successfully develop and conduct nonclinical safety, pharmacokinetics, and immunogenicity assessments of multiple types of products, including small molecules, antibodies, bispecific T cell-engagers, oncolytic viruses, siRNAs, and engineered T cells.

Before focusing on providing consulting services, he was Vice President, Development Sciences at Sonoma Biotherapeutics, where he oversaw nonclinical safety, immunogenicity, pharmacokinetics, and clinical pharmacology functions. Sonoma Biotherapeutics is developing engineered regulatory T cells for autoimmune diseases.

Prior to joining Sonoma Bio, he worked in Translational Safety and Bioanalytical Sciences at Amgen Inc., where he most recently served as Executive Director of Translational Safety. He was responsible for leading a team of toxicologists and laboratory-based scientists responsible for the nonclinical safety assessment of multiple types of products (small molecules, antibodies, oncolytic viruses, siRNAs, and engineered T cells) from lead optimization through post-marketing phases. In that function, Hervé also contributed to the preparation of first-in-human oncology clinical study protocols for the proper integration of nonclinical data and translational safety information. Hervé also supported oncology-related business development efforts through fit-for-purpose evaluations. Prior to this, Hervé was a Principal Scientist and Scientific Director in Translational Safety at Amgen, where he served as Project Team Toxicologist.

Prior to joining Amgen, Dr. Lebrec served at 3M Pharmaceuticals, initially as a Research Specialist and then as Pathology and Toxicology Department Manager, with a focus on the nonclinical safety assessment of small-molecule Toll-like receptor agonists.

Prior to joining industry, Dr. Lebrec served as Assistant Professor at the University Paris XI. He received his Doctorate in Pharmacy and his PhD in Toxicology from the same university. He is a diplomate of the American Board of Toxicology.

Dr. Lebrec’s research work and scientific interests have notably focused on immune-related safety issues; he co-chairs the Immunosafety Technical Committee of the nonprofit HESI (Health and Environmental Sciences Institute) and is President of the Biotechnology Specialty Section of the Society of Toxicology. He has contributed to 60 peer-reviewed publications, which can be accessed here: Dr. Hervé Lebrec’s publications.

Mark N. Milton, PhD

Mark N. Milton, PhD

Consultant

Lake Boon Pharmaceutical Consulting, LLC

Dr. Mark Milton retired in March 2022 after almost 31 years in the pharmaceutical industry. Over the course of his career, he managed a GLP-compliant bioanalytical laboratory and provided nonclinical and clinical support for LMW compounds, biologics, cell therapies, and gene therapies. He now provides gene therapy and biologics nonclinical and clinical consulting services through Lake Boon Pharmaceutical Consulting, LLC.

Dr. Milton received a BSc in Biochemistry and Soil Science from UCNW, Bangor, and an MSc in Toxicology and a PhD in Biochemical Toxicology from the University of Surrey, England. Dr. Milton started his career at GD Searle in Skokie, Illinois, before moving to Millennium Pharmaceuticals in Cambridge, Massachusetts. He then moved to Tempo Pharmaceuticals (Cerulean Pharmaceuticals) before joining Novartis in January 2009, where he held leadership positions in ocular PK/IG, the PK/PD/IG of biologics, and gene therapies, as well as representing PKS Sciences on the Cell & Gene Therapy Steering Committee and Novartis’s First in Human Review Board. Dr. Milton held a leadership position in the AAV Immunogenicity Task Force and the Immunogenicity Advisory Group. Dr. Milton supported many of Novartis’s gene therapy projects and anti-complement programs, wrote the nonclinical PK summary for the Kymriah BLA, was involved in the in-licensing of Luxturna and the acquisitions of Avexis and Gyroscope, and provided nonclinical and clinical PK and immunogenicity support to Zolgensma post-market and for intrathecal administration of OAV101.

Dr. Milton is a past chair of the BioSafe PKPD EWG, a member of the BioSafe LC and IQ Board of Directors, a member of the AAPS Pre-existing Antibody and Immunogenicity Risk Assessment Working Groups, and was the BIO observer to the ICHS3A Q&A WG.

He has published over 30 peer-reviewed publications and book chapters and presented extensively on the development of NCEs, biologics, and gene therapies. His interests include the PK/PD and immunogenicity of biotherapeutics, the contribution of PK (biodistribution) and IG to the development of gene therapies, ocular immunology, the selection of the clinical starting dose based upon the MABEL calculation, and alternative designs for FIH clinical trials of monoclonal antibodies in healthy volunteers.

Jay Tibbitts, DVM, PhD

Jay Tibbitts, DVM, PhD

Executive Director of Drug Metabolism and Pharmacokinetics

Gilead Sciences, Inc.

Dr. Jay Tibbitts is an Executive Director in the Drug Metabolism and Pharmacokinetics Department at Gilead Sciences. Prior to joining Gilead, he led Nonclinical PKPD organizations at AbbVie, UCB, and Genentech, led Nonclinical Development, and served as a Project Leader at both Surrozen, Inc and Lycia Therapeutics. He has dedicated much of his career to the quantitative pharmacology and development of both small- and large-molecule drugs across multiple indications, and has contributed to the filing of more than 20 INDs and several BLAs. Dr. Tibbitts received his PhD in pharmaceutical chemistry from the University of California, San Francisco, and a DVM from Ohio State University.

John L. Vahle, DVM, PhD, Diplomate ACVP

John L. Vahle, DVM, PhD, Diplomate ACVP

Senior Research Fellow

Eli Lilly and Company

Dr. John Vahle received his veterinary medical degree from the University of Missouri in 1988 and his doctorate in veterinary pathology from Iowa State University in 1996.  He became a Diplomate of the American College of Veterinary Pathologists in 1995 and joined Lilly as a senior pathologist in 1996. He currently serves as a Senior Research Fellow at Lilly.

Dr. Vahle has over 25 years of experience in pathology and toxicology and has served in a variety of roles including study pathologist, project pathologist, toxicology project leader, and regulatory toxicology advisor.  His areas of interest include carcinogenicity assessments, biotherapeutics development, bone toxicology, and pathology. Dr. Vahle is active in various professional societies and consortia and is a past Councilor of the STP, past Chair of the BioSafe Organization, and a member of the steering committee for the international toxicologic pathology nomenclature initiative, INHAND.  Based on his experience in carcinogenicity testing, Dr. Vahle served as a member of the ICH Expert Working Group assessing carcinogenicity testing paradigms for pharmaceuticals. Dr. Vahle’s publications have focused on toxicologic pathology of the endocrine and musculoskeletal systems as well as approaches to carcinogenicity assessment.

Mary Ellen Cosenza, PhD, MS, DABT, ATS, ERT, RAC, MEC Regulatory & Toxicology Consulting, LLC

Jeanine Bussiere, PhD, DABT, ATS, Amgen Inc.

Buay Permpoontaweesup, ACT Staff Liaison

Registration Fees

Early-Bird Registration
(Received by April 22)
Regular Registration
(Begins April 23)
ACT Member $1,650 $1,750
ACT Student or Postdoc Member $895 $995
Nonmember $1,950$2,050
Government* $1,650 $1,750
ACT Member Group Rate**
(3 or more from same company)
$1,550$1,650
ACT Member Group Rate**
(10 or more from same company)
$1,450$1,550
Nonmember Group Rate**
(3 or more from same company)
$1,750 $1,850
Nonmember Group Rate**
(10 or more from same company)
$1,650$1,750

Fees are accessed according to the membership status at the time of purchase (there are no exceptions and there are no refunds).

*Government Registration Policy: The government registration rate is specifically designated for federal, state, or local employees of government departments/agencies who are actively participating in the course as official government personnel. Employees of public academic institutions, nonprofit institutions, or government contractors do not qualify for the discounted government rate. To register under the government rate, individuals must use their government-affiliated email address for verification purposes. ACT may request further documentation of government employment before the registration is finalized. If you are unsure you qualify for the government rate, please email ACT Headquarters before processing your payment online.

**Group Rate Registration: To take advantage of the group rate: Please send your completed registration forms to ACT Headquarters. You will not be able to select the group rate through the online registration. All three forms (or more) should be emailed at the same time.

Refund Policy: $100 Processing Fee will be charged if canceled before June 11, 2027, 50% refund if canceled before July 9, 2027; After July 10, 2027, no fees will be refunded. 

Register

Registration Form

Course Location

Gaithersburg Marriott Washingtonian Center
9751 Washingtonian Boulevard
Gaithersburg, MD 20878

Transportation Information

Hotel

Gaithersburg Marriott Washingtonian Center
9751 Washingtonian Boulevard
Gaithersburg, MD 20878
Tel: 301.590.0044 | 301.590.6104

Housing Deadline

Please refer to the ACT Room Block to make your housing reservation. The ACT meeting rate of $199 (plus tax) is offered over the dates of June 13–16, 2027, based on availability, and reservations must be made by May 14, 2027.

Daily continental breakfast, snack breaks, and lunch are provided as part of the registration. To disclose dietary restrictions, allergies, and/or accessibility needs please email ACT Headquarters by May 14, 2027. ACT will do its best to accommodate but cannot guarantee requests will be granted.

Key:

Complete
Failed
Available
Locked
Course Materials Will Be Available Approximately Two Weeks Before the Course Begins.
In-Person Course
06/14/2027 at 8:00 AM (EDT)   |  2 days, 9 hours
06/14/2027 at 8:00 AM (EDT)   |  2 days, 9 hours